Answers are grounded in this paper and cite their sources.
Mantle cell lymphoma (MCL) is a rare, aggressive non-Hodgkin lymphoma (NHL) characterized by considerable biological and clinical heterogeneity. A number of baseline clinical histological and biological predictors have been identified including MIPI, proliferation index, blastoid histology and genetic mutations. In recent years, minimal residual disease (MRD) detection has gained considerable interest as a post-treatment outcome predictor and a considerable amount of data has been generated in the field. This review will discuss major technical advances and significant clinical messages that have been derived from the application of MRD monitoring to clinical trials during the last decade. Potential integration of MRD results with metabolic response data, as well as baseline clinical, genetic, and microenvironmental parameters will also be discussed.
No takes yet. Share an insight, caveat, or question.
Ladetto et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: